Company intelligence / Profile preview

Scriptgen Pharmaceuticals

Waltham, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Scriptgen Pharmaceuticals was a biotechnology company focused on discovering small molecule drugs that target RNA and RNA-protein interactions. Founded in 1996, the company developed a proprietary high-throughput screening platform to identify compounds capable of modulating gene expression at the translational level. Its primary therapeutic focus included infectious diseases, such as Hepatitis C and HIV, as well as oncology. In 2000, Scriptgen was acquired by Anadys Pharmaceuticals, which integrated Scriptgen's RNA-targeting technology into its own drug discovery pipeline.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Genzyme

Beyond the preview

Go deeper on Scriptgen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scriptgen Pharmaceuticals.

Explore the full profile